MOTS-c

A mitochondrial peptide investigated in research on AMPK, metabolism, physical activity and ageing

Overview

MOTS-C is a 16-amino-acid peptide encoded in a stretch of mitochondrial DNA that lies within the 12S rRNA sequence. Its full name, Mitochondrial Open Reading Frame of the 12S rRNA-c, places it among the mitochondrial-derived peptides, a family of peptides that originate in the mitochondria [1]. Interest in MOTS-C rests on the idea that the mitochondrion does more than generate ATP: it is also an organelle that emits biological signals influencing both the cell and the organism as a whole. Mitochondrial peptides may take part in mitochondria-to-nucleus communication, in the regulation of metabolic stress, in inflammation, in insulin sensitivity and in ageing processes [1,2,5]. What is known about MOTS-C comes mostly from cell studies, animal studies and biological measurements in humans. Evidence indicates that its levels or expression shift with physical activity and across different metabolic conditions, but this is not proof that external administration has clinical efficacy in humans [4,6].

Biological Mechanism

A leading mechanism investigated for MOTS-C involves the folate pathway and purine biosynthesis. The original study reported that MOTS-C acts on these pathways in a way linked to a rise in endogenous AICAR and to AMPK activation [1]. AMPK serves as a key cellular energy sensor, switched on when the cell faces an energetic load or needs to work more efficiently. Once AMPK is active, the cell tends to step up energy-generating processes such as fatty acid oxidation and glucose uptake, while scaling back energy-consuming processes that are not essential at that point. This connection between MOTS-C and AMPK accounts for the interest in the peptide in relation to insulin sensitivity, skeletal muscle, physical activity and metabolism [1,4,5]. A 2018 study reported that, under metabolic stress, MOTS-C can move into the cell nucleus and influence the expression of stress-response genes, including pathways associated with NRF2 and with antioxidant response elements [2]. The finding matters because it positions MOTS-C within a wider system of cellular adaptation rather than as a lone metabolic switch.

Research Evidence

In a 2015 study in Cell Metabolism, giving MOTS-C to mice in models of high-fat feeding and metabolic ageing was associated with better insulin sensitivity, less diet-induced obesity and altered skeletal muscle metabolism [1]. A 2019 study suggested that MOTS-C shapes the plasma metabolite profile and enhances insulin sensitivity in experimental models, with effects on lipid pathways and a range of metabolites [3]. In 2021, a Nature Communications paper described MOTS-C as a peptide responsive to physical activity and as a regulator of age-related functional decline in mouse models [4]. A subsequent study from 2026 investigated how MOTS-C affects mitochondrial bioenergetics in muscle and proposed that some of its effects rely on PGC-1α and AMPK [5]. In humans, a 2024 systematic review and meta-analysis identified associations between MOTS-C levels and metabolic conditions, while also highlighting inconsistencies across studies and populations [6].

Mitochondria–Nucleus Signalling and the Connection to Exercise

A notable characteristic of MOTS-C is that it links the mitochondrial genome to nuclear responses. Although most mitochondria-associated proteins are encoded in the nucleus, MOTS-C shows that the mitochondrion can itself supply peptide signals that feed into wider regulatory systems [1,2]. Its movement into the nucleus under metabolic stress, reported in 2018, points to a role as part of an adaptive mechanism rather than as a single metabolic molecule [2]. The connection with physical activity is especially significant because it situates MOTS-C within a whole network of biological signals: exercise changes ATP, NAD, calcium, ROS, AMPK, PGC-1α, hormones, myokines and inflammatory markers. So when a study finds that physical activity raises MOTS-C expression or levels, it does not follow that the peptide alone accounts for the effects of training [4]; it is better understood as one of several possible markers or mediators of muscular and metabolic adaptation. In mouse models, MOTS-C has been linked with improved physical function at various ages and with changes in skeletal muscle metabolism [4]. The 2026 study added a bioenergetic dimension, proposing that certain muscle effects depend on AMPK and PGC-1α and involve more efficient mitochondria rather than simply more of them [5]. The difference between mitochondrial quality and quantity is meaningful, since a tissue may hold many mitochondria and still function inefficiently. In humans, most of the data come not from therapeutic intervention trials but from level measurements, statistical associations and responses to physical activity [4,6], leaving a gap between compelling biology and clinical conclusions. The 2024 meta-analysis stressed the inconsistency between studies, including differences by metabolic state, measurement method and population [6]. The field therefore remains at a point where MOTS-C aids understanding of metabolism and ageing but does not support broad medical conclusions.

Safety & Regulation

Clinical information on MOTS-C in humans remains limited. Measuring blood levels of the peptide, or a change in its expression after physical activity, is not the same as demonstrating that external exposure is effective or safe. Questions around pharmacokinetics, degradation, immunogenicity, exposure ranges and long-term effects have not been adequately answered. The FDA states that no adequate human exposure data have been identified for drug products containing MOTS-C, and it raises concerns about immunogenicity, peptide-related impurities and characterisation of the active substance in the compounding context [7]. In competitive sport, substances that act on AMPK and metabolism may also fall within anti-doping rules, which makes regulatory distinctions important [8].

Biomarker or Intervention? An Important Distinction

Evidence that MOTS-C levels shift with physical activity or metabolic state does not show that the peptide directly causes any change in health [4,6]. It might be a mediator, a marker, a by-product of energetic stress or one element of a broad feedback system. The distinction matters because popular discussion often recasts molecules that respond to training as 'training substitutes,' when in reality the biology of exercise involves hundreds of pathways working in concert. Metabolic associations in humans are not uniform either. The 2024 review and meta-analysis found links between MOTS-C and conditions such as diabetes and obesity, but the direction was neither simple nor consistent across all studies [6]. Such variation may reflect differences in age, sex, BMI, physical activity, measurement method, background inflammation or metabolic disease. At present, then, high or low MOTS-C levels cannot be used as a diagnosis or as a basis for a therapeutic recommendation. For ageing research, MOTS-C is of interest because it highlights a link between mitochondria, skeletal muscle and stress resistance. Age-related functional decline does not stem from one pathway alone but from changes in mitochondria, chronic inflammation, loss of muscle mass, neural changes, hormones and movement; MOTS-C adds a layer to this research without explaining the ageing process on its own. On bone and osteoporosis, a topic that also features in recent regulatory discussions of MOTS-C, the evidence is at an even earlier stage than for metabolism and muscle [7]. A plausible biological link runs through cellular energy, inflammation and mitochondrial function, but there is as yet no broad clinical basis for describing a direct effect on bone density or fracture risk in humans.

Summary

MOTS-c is a mitochondrial peptide investigated in research on mitochondria-nucleus communication, the AMPK pathway, metabolic stress and ageing [1-5]. The preclinical findings are of interest, but human data remain limited and inconsistent [6]. Its principal value lies in research into how mitochondria influence metabolism; this material is supplied for laboratory research use only.

Selected Research Sources

1. Lee C. et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015. PMID: 25738459
2. Kim K.H. et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism, 2018. PMID: 29983246
3. Kim S.J. et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiological Reports, 2019. PMID: 31293078
4. Reynolds J.C. et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021. PMID: 33473109
5. Gudiksen A. et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free Radical Biology and Medicine, 2026. PMID: 41520850
6. The correlation between mitochondrial derived peptide and metabolic states: a systematic review and meta-analysis. PubMed, 2024. PMID: 39160573
7. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Entry for MOTS-C. FDA.gov
8. World Anti-Doping Agency. The Prohibited List. Section on metabolic modulators. WADA-ama.org